Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Upper GI is bringing some of the biggest practice-changing data to ESMOGI26.
Here are the Top 5 Upper GI Cancer abstracts I’m watching most closely.
1. 493O | STAR-221
Can domvanalimab + zimberelimab + chemotherapy outperform nivolumab + chemotherapy in first-line HER2-negative advanced gastric/GEJ adenocarcinoma?
2. 494O | HERIZON-GEA-01 (HRQoL)
Do the survival gains with zanidatamab + chemotherapy ± tislelizumab also translate into better quality of life for HER2-positive disease?
3. 495RO | HERIZON-GEA-01 (PFS2 Analysis)
Does first-line zanidatamab continue to provide benefit even after subsequent lines of therapy?
4. 496RO | EORTC ASPIRE
Can different PD-L1 assays and scoring systems be used interchangeably in gastroesophageal adenocarcinoma?
5. 344RO | Futibatinib + Zimberelimab + Chemotherapy
An early look at a novel first-line combination for advanced biliary tract cancer that could influence the broader upper GI treatment landscape.
Which upper GI abstract are you looking forward to the most?”
Other articles about GI Oncology on OncoDaily.